Menu +

Tag: rate

Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

• ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), compared with crizotinib (45.5%) • Data confirm longer-term efficacy of Alecensa, both in patients with or without central nervous system metastases at baseline Roche (SIX: RO, ROG; OTCQX: RHHBY) on […]